BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1000
- Registration Number
- NCT03521895
- Locations
- 🇩🇪
Many locations, Multiple Locations, Germany
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT03517956
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇸🇬National University Hospital, Singapore, Singapore
🇪🇸Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT03517930
- Locations
- 🇺🇸
Frontage Clinical Services, Secaucus, New Jersey, United States
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 29
- Registration Number
- NCT03517943
- Locations
- 🇺🇸
Frontage Clinical Services, Secaucus, New Jersey, United States
An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks
- Conditions
- Foot Orthoses
- Interventions
- Device: BPI1000013
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT03507478
- Locations
- 🇺🇸
Stephens & Associates, Inc., Richardson, Texas, United States
🇺🇸Thomas J. Stephens & Associates, Inc., Phoenix, Arizona, United States
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)Advanced Recurrent Malignant Peritoneal Epithelioid MesotheliomaAdvanced Recurrent Serous Ovarian CancerAdvanced Recurrent Malignant Pleural Epithelioid Mesothelioma
- Interventions
- Drug: BAY2287411
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT03507452
- Locations
- 🇫🇮
HUS, Meilahden sairaala, Helsinki, Finland
🇳🇱Nederlands Kanker Instituut, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
REALIsM-HF Pilot Study
- Conditions
- Heart Failure
- Interventions
- Device: AVIVO Mobile Patient Management (MPM) SystemDevice: VitalPatch biosensorDevice: DynaPort Move Monitor
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT03507439
- Locations
- 🇩🇪
Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇩🇪Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 74
- Registration Number
- NCT03504982
- Locations
- 🇩🇪
Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany
🇳🇱Center for Human Drug Research, Leiden, Netherlands
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
Copanlisib Chinese PK Study
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT03498430
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
- Conditions
- PsoriasisHealthy Volunteers
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT03493269
- Locations
- 🇩🇪
PAREXEL GmbH, Berlin, Germany
🇩🇪Charité Research Organisation GmbH, Berlin, Germany